AR044315A1 - Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido - Google Patents

Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido

Info

Publication number
AR044315A1
AR044315A1 ARP040101622A ARP040101622A AR044315A1 AR 044315 A1 AR044315 A1 AR 044315A1 AR P040101622 A ARP040101622 A AR P040101622A AR P040101622 A ARP040101622 A AR P040101622A AR 044315 A1 AR044315 A1 AR 044315A1
Authority
AR
Argentina
Prior art keywords
polypeptide
agent
prevent
tissue changes
accompanying diseases
Prior art date
Application number
ARP040101622A
Other languages
English (en)
Inventor
Kazuhiro Sakurada
Yoji Yamada
Hiroshi Ando
Hidetaka Sato
Hiromi Yokoyama
Masahiko Ishihara
Ichiro Miki
Akiko Yoshimatsu
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of AR044315A1 publication Critical patent/AR044315A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)

Abstract

Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos, que comprende un polipéptido que tiene actividad del factor estimulante de colonias de granulocitos como ingrediente activo, y un medicamento para movilizar una célula madre multipotente desde un tejido hacia la sangre periférica, que comprende un polipéptido que tiene actividad del factor estimulante de colonias de granulocitos como ingrediente activo, y ácido retinoico, un derivado del mismo o un inhibidor de CXCR4, como por ejemplo AMD-3100 o un derivado del mismo.
ARP040101622A 2003-05-16 2004-05-14 Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido AR044315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003139604 2003-05-16

Publications (1)

Publication Number Publication Date
AR044315A1 true AR044315A1 (es) 2005-09-07

Family

ID=33447348

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101622A AR044315A1 (es) 2003-05-16 2004-05-14 Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido

Country Status (10)

Country Link
US (1) US20070172447A1 (es)
EP (1) EP1632241A4 (es)
JP (1) JPWO2004100972A1 (es)
KR (1) KR20060018851A (es)
CN (1) CN1816345A (es)
AR (1) AR044315A1 (es)
AU (1) AU2004238146A1 (es)
CA (1) CA2526025A1 (es)
TW (1) TW200505408A (es)
WO (1) WO2004100972A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114594A1 (en) 2009-05-14 2012-05-10 Keiichi Fukuda Muscle repair promoter
JP6570833B2 (ja) * 2011-08-29 2019-09-04 アンスティトゥー ナショナル ドゥ ラ サンテ エ ドゥ ラ レシェルシュ メディカル（イエヌエスエエールエム） 人工沿軸中胚葉前駆（ｉＰＡＭ）細胞を調製する方法及びその使用
EP2811939B8 (en) * 2012-02-10 2017-11-15 CVDevices, LLC Products made of biological tissues for stents and methods of manufacturing
RU2650962C2 (ru) 2012-06-07 2018-04-18 Чилдрен'З Хоспитал Лос Анджелес Способы лечения нейтропении с применением ретиноидных агонистов
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
WO2015110536A1 (en) * 2014-01-22 2015-07-30 Reponex Pharmaceuticals Aps Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma
EP3107533A4 (en) * 2014-02-18 2017-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
EP3050570A1 (en) * 2015-01-31 2016-08-03 Neurovision Pharma GmbH Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
WO2018014017A1 (en) * 2016-07-15 2018-01-18 New Amsterdam Sciences Substance and method for treating idiopathic pulmonary fibrosis and related interstitial lung diseases
WO2018014016A1 (en) * 2016-07-15 2018-01-18 New Amsterdam Sciences Substance and method for treating radiation exposure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
JP3537151B2 (ja) * 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
ATE446767T1 (de) * 1999-02-12 2009-11-15 Univ Washington Gm-csf zur behandlung von morbus crohn
EP1074634B1 (en) * 1999-07-09 2002-10-02 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AR027509A1 (es) * 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
JP5414958B2 (ja) * 2000-06-05 2014-02-12 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用
JP2002020298A (ja) * 2000-07-10 2002-01-23 Junkanki Kenkyusho:Kk 血管新生促進剤
JP3866197B2 (ja) * 2000-09-13 2007-01-10 中外製薬株式会社 虚血性疾患治療剤
AU2002316201A1 (en) * 2001-06-07 2002-12-16 Quark Biotech, Inc. Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
US20040265971A1 (en) * 2001-11-19 2004-12-30 Hidetaka Sato Drug mobilizing pluripotent stem cells from tissue into peripheral blood

Also Published As

Publication number Publication date
AU2004238146A1 (en) 2004-11-25
KR20060018851A (ko) 2006-03-02
CA2526025A1 (en) 2004-11-25
WO2004100972A1 (ja) 2004-11-25
US20070172447A1 (en) 2007-07-26
JPWO2004100972A1 (ja) 2006-07-13
EP1632241A4 (en) 2009-07-22
TW200505408A (en) 2005-02-16
EP1632241A1 (en) 2006-03-08
CN1816345A (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
CR20110128A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar a un paciente de acuerdo con la respuesta predicha
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
NI200900145A (es) Formulaciones de dosis unitaria y metodos para el tratamiento de la trombosis con un inhibidor oral del factor xa.
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
CR20110353A (es) Compuestos de tiazolopiridina moduladores de sirtuina referencia cruzada
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
EA200971053A1 (ru) Способы лечения кожных язв
CR11724A (es) Agente para tratar enfermedades
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
AR044315A1 (es) Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido
HK1205677A1 (en) Mesenchymal stem cells and uses therefor
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
EA201992759A1 (ru) Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения
AR061269A1 (es) Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
RU2015148636A (ru) Модуляция активности гепарин-связывающего эпидермального фактора роста для заживления барабанной перепонки
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
WO2006047625A3 (en) Method to promote wound healing

Legal Events

Date Code Title Description
FA Abandonment or withdrawal